Analyst Reco. Prelude Therapeutics Incorporated

Equities

PRLD

US74065P1012

Market Closed - Nasdaq Other stock markets 04:00:00 2024-07-09 pm EDT			5-day change	1st Jan Change
3.46 ^USD	+0.29%		-8.22%	-18.97%

Jul. 09	Prelude Therapeutics Inks Deal With Merck for Phase 2 Study to Evaluate its SMARCA2 Degrader With Keytruda	MT
Jul. 09	Prelude Therapeutics Announces Clinical Collaboration with Merck to Evaluate PRT3789 in Combination with KEYTRUDA® (pembrolizumab) in Patients with SMARCA4-Mutated Cancers	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Barclays Downgrades Prelude Therapeutics to Underweight From Equalweight With $3 Price Target	Jun. 20	MT
JMP Securities Starts Prelude Therapeutics With Market Outperform Rating, $7 Price Target	Mar. 13	MT
HC Wainwright Downgrades Prelude Therapeutics to Neutral From Buy, Price Target is $5	Feb. 20	MT
Morgan Stanley Downgrades Prelude Therapeutics to Underweight From Equalweight, Cuts Price Target to $4 From $10	Dec. 19	MT
HC Wainwright Trims Prelude Therapeutics' Price Target to $5 From $6, Keeps Buy Rating	Nov. 07	MT
HC Wainwright Adjusts Price Target on Prelude Therapeutics to $6 From $17, Keeps Buy Rating	23-10-19	MT
Barclays Adjusts Price Target on Prelude Therapeutics to $5 From $7, Maintains Equalweight Rating	23-08-04	MT
HC Wainwright Adjusts Price Target on Prelude Therapeutics to $17 From $15, Maintains Buy Rating	23-03-17	MT
HC Wainwright Adjusts Prelude Therapeutics' Price Target to $15 From $16, Keeps Buy Rating	22-11-17	MT
Morgan Stanley Trims Price Target on Prelude Therapeutics to $10 From $11, Maintains Equalweight Rating	22-11-15	MT
Morgan Stanley Downgrades Prelude Therapeutics to Equalweight From Overweight, Cuts Price Target to $11 From $19	22-09-09	MT
Jefferies Initiates Prelude Therapeutics at Buy With $9 Price Target	22-07-29	MT
HC Wainwright Adjusts Prelude Therapeutics Price Target to $16 From $62, Maintains Buy Rating	22-05-12	MT
Morgan Stanley Adjusts Prelude Therapeutics Price Target to $19 From $20, Maintains Overweight Rating	22-03-17	MT
BofA Securities Downgrades Prelude Therapeutics to Neutral From Buy, Adjusts Price Target to $10 From $50	22-03-15	MT
Barclays Downgrades Prelude Therapeutics to Equalweight From Overweight, Adjusts Price Target to $12 From $20	22-02-28	MT
Barclays Adjusts Prelude Therapeutics' Price Target to $20 From $33, Reiterates Overweight Rating	21-11-17	MT
PRELUDE THERAPEUTICS INCORPORATED : Morgan Stanley Upgrades Prelude Therapeutics to Overweight Rating From Equal-Weight, Adjusts Price Target to $35 From $60	21-10-11	MT
PRELUDE THERAPEUTICS INCORPORATED : Barclays Adjusts Prelude Therapeutics' Price Target to $33 from $80, Keeps Overweight Rating	21-10-08	MT
PRELUDE THERAPEUTICS INCORPORATED : BofA Securities Upgrades Prelude Therapeutics to Buy From Neutral; Price Target is $60	21-07-27	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Prelude Therapeutics Incorporated

Equities

PRLD

US74065P1012

Analyst Reco.

Filters